Although canagliflozin does not have an HF indication, this study adds important supporting evidence about the beneficial effects of the class of SGLT2 inhibitors on improving HF symptoms, with novel data indicating that these benefits can occur as early as 2 weeks after initiation of therapy. Here, SLC5A2 is linked to hydrops fetalis.